<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136210">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01955980</url>
  </required_header>
  <id_info>
    <org_study_id>12082.102</org_study_id>
    <nct_id>NCT01955980</nct_id>
  </id_info>
  <brief_title>Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis</brief_title>
  <official_title>A Pilot Study to Investigate the Potential of Buparid/PARI SINUS Versus Budes® Nasal Spray to Avoid or Postpone Sinus Surgery in Adult Patients With Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pari Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pari Pharma GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study should create data for the selection of a clinically relevant endpoint to assess
      the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic
      Rhinosinusitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Avoidance or postponing of sinus surgery</measure>
    <time_frame>From baseline  to week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Health-related quality of life</measure>
    <time_frame>From baseline to week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessments will be done using the Sino-Nasal outcome Test 22 (SNOT 22)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal obstruction</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rhinomanometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation of the nasal mucosa and paranasal sinus</measure>
    <time_frame>Changes from Baseline at Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of the thickness of the mucosa using Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Buparid; Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buparid 1mg budesonide/2 ml nebulizer solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budes; Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budes Nasal Spray 50 µg budesonide/pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Inhalation</description>
    <arm_group_label>Buparid; Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Nasal Spray</description>
    <arm_group_label>Budes; Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with confirmed diagnosis of chronic rhinosinusitis

          -  Patient without alternative other than sinus surgery

          -  Patient's written informed consent obtained prior to any screening or study-specific
             procedure

          -  Male or female, ≥ 18 years of age

          -  Patient is able to undergo nasal therapy without restrictions

          -  Capable to correctly use the PARI SINUS device

          -  Capable of understanding the purpose and risk of the clinical trial

          -  Female patients with childbearing potential must have a negative urine pregnancy test
             prior to first IMP administration.

          -  Patient is able to participate in the study according to Investigator's opinion

        Exclusion Criteria:

          -  Patients with cystic fibrosis

          -  Patients with polyposis nasi grade I-IV

          -  Patients with prior FESS (Functional Endoscopic Sinus Surgery)

          -  Patients with demonstrated allergies against aeroallergens

          -  Pregnant or breastfeeding women

          -  Any active invasive bacterial, viral or fungal infection within one week prior to
             first investigational medicinal product (IMP) administration

          -  No clinically relevant abnormal parameters of vital signs, blood biochemistry or
             renal/hepatic function

          -  Unlikely to comply with visits, inhalation procedures or other measurements scheduled
             in the protocol

          -  Receipt of an investigational drug as part of a clinical trial within 4 weeks prior
             to first administration of IMP

          -  Any co-existing medical condition that in the Investigator's judgement will
             substantially increase the risk associated with the patient's participation in the
             clinical trial

          -  Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary procedures

          -  Drug or alcohol abuse

          -  End-stage malignancies

          -  Known hypersensitivity to Budesonide

          -  Patients with topical or oral steroid therapy within the last 3 months

          -  Patients needing &gt; 1 mg/day Budesonide (or steroidal equivalent) for therapy of
             asthma

          -  Patients on therapy with intranasal steroids, leukotriene-receptor antagonists,
             decongestants, antihistamines or antibiotics

          -  Patients with frequent epistaxis (&gt; 1 episode per week)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Canis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Goettingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Prante</last_name>
    <phone>+49 89 742846</phone>
    <phone_ext>830</phone_ext>
    <email>s.prante@pari.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerhard Boerner</last_name>
    <phone>+49 89 742846</phone>
    <phone_ext>59</phone_ext>
    <email>g.boerner@pari.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Canis, MD</last_name>
      <phone>+49 551 39</phone>
      <phone_ext>22801</phone_ext>
      <email>martin.canis@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Canis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sven Becker, MD</last_name>
      <phone>+49 89 7095</phone>
      <phone_ext>0</phone_ext>
      <email>sven.becker@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Sven Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>September 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRS</keyword>
  <keyword>without polyposis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
